The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system ...

Messenger RNA (mRNA) therapeutics hold significant promise for the future of personalized cancer treatment, but persistent ...

Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their ...

Artificial intelligence is getting really good at helping doctors diagnose problems and even discover new drugs faster. It ...

RNA COVID-19 vaccines — originally developed to protect against the coronavirus — may be providing an additional, unexpected health advantage.

However, the research team head cautioned that it is still too early to recommend the mRNA COVID-19 vaccine as a standard part of cancer therapy.

As BioNTech works to establish a production footprint for mRNA vaccines in Africa, two EU groups have offered financial backing to the company's efforts. The European Commission pledged a 35 million ...

Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

Stone jauntily observes: "5 billion of us got Covid vaccines. Apparently we all have 2 months left to live. Better make the ...

In the latest trading session, Moderna (MRNA) closed at $26.85, marking a -2.33% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.53%. Elsewhere, the Dow ...